|
1
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd FA, Pereira JR, Ciuleanu T, et
al: Erlotinib in previously treated non-small-cell lung cancer. N
Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaft JE, Oxnard GR, Sima CS, Kris MG,
Miller VA and Riely GJ: Disease flare after tyrosine kinase
inhibitor discontinuation in patients with EGFR-mutant lung cancer
and acquired resistance to erlotinib or gefitinib: implications for
clinical trial design. Clin Cancer Res. 17:6298–6303. 2011.
View Article : Google Scholar
|
|
6
|
Van den Abbeele AD, Badawi RD, Manola J,
et al: Effects of cessation of imatinib mesylate (IM) therapy in
patients (pts) with IM-refractory gastrointestinal stromal tumors
(GIST) as visualized by FDG-PET scanning. J Clin Oncol. 22:abs.
30122004.
|
|
7
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
National Comprehensive Cancer Network
(NCCN). NCCN Clinical Practice Guidelines in Oncology. Available
at: http://www.nccn.org/index.asp.
Accessed January 4, 2013
|
|
9
|
Goldberg SB, Oxnard OR, Digumarthy S,
Muzikansky A, Jackman DM, Lennes IT and Sequist LV: Chemotherapy
with erlotinib or chemotherapy alone in advanced NSCLC with
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). J
Clin Oncol. 30(Suppl): abs. 75242012.PubMed/NCBI
|
|
10
|
Shepherd FA, Dancey J, Ramlau R, et al:
Prospective randomized trial of docetaxel versus best supportive
care in patients with non-small-cell lung cancer previously treated
with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103.
2000.
|
|
11
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim ES, Hirsh V, Mok T, et al: Gefitinib
versus docetaxel in previously treated non-small-cell lung cancer
(INTEREST): a randomised phase III trial. Lancet. 22:1809–1818.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maruyama R, Nishiwaki Y, Tamura T,
Yamamoto N, et al: Phase III study, V-15-32, of gefitinib versus
docetaxel in previously treated Japanese patients with
non-small-cell lung cancer. J Clin Oncol. 26:4244–4252. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Shi Y, Zhang L, et al: A
randomized, double-blind phase III study of icotinib versus
gefitinib in patients with advanced non-small cell lung cancer
(NSCLC) previously treated with chemotherapy (ICOGEN). J Clin
Oncol. 29(Suppl 15): abs. 75222011.PubMed/NCBI
|
